Scientists test new diabetes drug in people with kidney problems

NCT ID NCT07385547

Summary

This early-stage study aims to understand how kidney function affects the body's processing of a new long-acting diabetes drug called GL0034. Researchers will give a single dose to about 40 adults with varying levels of kidney health, from normal to severe impairment. The goal is to gather data to help doctors safely dose this medication for people with diabetes who also have kidney problems.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for TYPE II DIABETES MELLITUS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Orlando Clinical Research Center (OCRC)

    NOT_YET_RECRUITING

    Orlando, Florida, 32809, United States

  • Panax Clinical Research

    RECRUITING

    Miami Lakes, Florida, 33014, United States

  • Syneos Miami

    NOT_YET_RECRUITING

    Miami, Florida, 33136, United States

Conditions

Explore the condition pages connected to this study.